123 I-BMIPP, a Radiopharmaceutical for Myocardial Fatty Acid Metabolism Scintigraphy, Could Be Utilized in Bacterial Infection Imaging

• Published in: Pharmaceutics Vol. 14; no. 5
• Main Authors: Muranaka, Yuka, Mizutani, Asuka, Kobayashi, Masato, Nakamoto, Koya, Matsue, Miki, Takagi, Fumika, Okazaki, Kenichi, Nishi, Kodai, Yamazaki, Kana, Nishii, Ryuichi, Shikano, Naoto, Okamoto, Shigefumi, Maki, Hideki, Kawai, Keiichi
• Format: Journal Article
• Language: English
• Published: Switzerland 07.05.2022
• Subjects: bacterial imaging; 123I-BMIPP; nuclear medicine imaging; bacterial infection; SPECT
• ISSN: 1999-4923; 1999-4923

In this study, we evaluated the use of 15-(4- I-iodophenyl)-3(R,S)-methylpentadecanoic acid ( I-BMIPP) to visualize fatty acid metabolism in bacteria for bacterial infection imaging. We found that I-BMIPP, which is used for fatty acid metabolism scintigraphy in Japan, accumulated markedly in EC-14 similar to F-FDG, which has previously been studied for bacterial imaging. To elucidate the underlying mechanism, we evaluated changes in I-BMIPP accumulation under low-temperature conditions and in the presence of a CD36 inhibitor. The uptake of I-BMIPP by EC-14 was mediated via the CD36-like fatty-acid-transporting membrane protein and accumulated by fatty acid metabolism. In model mice infected with EC-14, the biological distribution and whole-body imaging were assessed using I-BMIPP and F-FDG. The I-BMIPP biodistribution study showed that, 8 h after infection, the ratio of I-BMIPP accumulated in infected muscle to that in control muscle was 1.31 at 60 min after I-BMIPP injection. In whole-body imaging 1.5 h after I-BMIPP administration and 9.5 h after infection, infected muscle exhibited a 1.33-times higher contrast than non-infected muscle. Thus, I-BMIPP shows potential for visualizing fatty acid metabolism of bacteria for imaging bacterial infections.